Author:
Cahn Pedro,Fink Valeria,Patterson Patricia
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Virology,Infectious Diseases,Oncology (nursing),Oncology,Hematology,Immunology
Reference12 articles.
1. Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir;Meanwell;J Med Chem,2018
2. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects;Nettles;J Infect Dis,2012
3. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068;Nowicka-Sans;Antimicrob Agents Chemother,2012
4. Model-based phase 3 dose selection for HIV-1 attachment inhibitor prodrug BMS-663068 in HIV-1-infected patients: population pharmacokinetics/pharmacodynamics of the active moiety, BMS-626529;Landry;Antimicrob Agents Chemother,2016
5. Pharmacokinetics of temsavir, the active moiety of the prodrug fostemsavir, in subjects with hepatic impairment, presented at ID week 2017, San Diego, 4–8th October 2017;Sevinsky;OFID,2017
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献